A detailed history of Dimensional Fund Advisors LP transactions in Pds Biotechnology Corp stock. As of the latest transaction made, Dimensional Fund Advisors LP holds 25,298 shares of PDSB stock, worth $55,655. This represents 0.0% of its overall portfolio holdings.

Number of Shares
25,298
Previous 39,633 36.17%
Holding current value
$55,655
Previous $116,000 17.24%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024

SELL
$2.93 - $4.23 $42,001 - $60,637
-14,335 Reduced 36.17%
25,298 $96,000
Q2 2024

Aug 09, 2024

SELL
$2.55 - $4.02 $20 - $32
-8 Reduced 0.02%
39,633 $116,000
Q1 2024

May 10, 2024

SELL
$3.85 - $6.59 $9,713 - $16,626
-2,523 Reduced 5.98%
39,641 $156,000
Q4 2023

Feb 07, 2024

SELL
$3.95 - $6.58 $7,813 - $13,015
-1,978 Reduced 4.48%
42,164 $209,000
Q3 2023

Nov 09, 2023

SELL
$4.8 - $6.4 $49,396 - $65,862
-10,291 Reduced 18.91%
44,142 $222,000
Q2 2023

Aug 09, 2023

SELL
$5.03 - $9.9 $1,443 - $2,841
-287 Reduced 0.52%
54,433 $273,000
Q1 2023

May 12, 2023

SELL
$5.68 - $11.99 $20,164 - $42,564
-3,550 Reduced 6.09%
54,720 $336,000
Q4 2022

Feb 09, 2023

BUY
$3.28 - $13.2 $91,475 - $368,134
27,889 Added 91.8%
58,270 $769,000
Q3 2022

Nov 10, 2022

SELL
$2.97 - $5.79 $2,343 - $4,568
-789 Reduced 2.53%
30,381 $90,000
Q2 2022

Aug 12, 2022

SELL
$3.05 - $6.68 $117,296 - $256,899
-38,458 Reduced 55.23%
31,170 $114,000
Q1 2022

May 13, 2022

BUY
$4.78 - $8.43 $166,329 - $293,338
34,797 Added 99.9%
69,628 $431,000
Q4 2021

Feb 09, 2022

BUY
$7.76 - $14.35 $270,288 - $499,824
34,831 New
34,831 $282,000

Others Institutions Holding PDSB

About PDS Biotechnology Corp


  • Ticker PDSB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 28,458,700
  • Market Cap $62.6M
  • Description
  • PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies...
More about PDSB
Track This Portfolio

Track Dimensional Fund Advisors LP Portfolio

Follow Dimensional Fund Advisors LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Dimensional Fund Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on Dimensional Fund Advisors LP with notifications on news.